Table of Content

 
Table Of Contents
 
1. Introduction to Cancer Antibody Combinations
  1.1 History, Development & Evolution
  1.2 Approved Cancer Antibody Combinations
 
2. Need of Antibody Combinations
 
3. Global Cancer Antibody Combinations Market & Clinical Development Insight
  3.1 Current Market Scenario
  3.2 Future Outlook
 
4. Global Antibody Combinations Market Insight by Region
  4.1 US
  4.2 China
  4.3 Europe
  4.4 Japan
  4.5 UK
  4.6 Canada
  4.7 South Korea
 
5. Global Cancer Antibody Combinations Clinical Trials Overview
  5.1 By Antibody Classification
  5.2 By Breakthrough Therapy & Fast Track Status
  5.3 By Company
  5.4 By Country
  5.5 By Indication
  5.6 By Phase
 
6. Global Antibody Combinations Market Insight by Indication
  6.1 Lung Cancer
  6.2 Melanoma
  6.3 Breast Cancer
  6.4 Hepatocellular Cancer
  6.5 Colorectal Cancer
  6.6 Renal Cell Carcinoma
  6.7 Lymphoma
  6.8 Leukemia
  6.9 Multiple Myeloma
 
7. Global Cancer Antibody Combinations Clinical Trials Insight  By Company, Indication & Phase
  7.1 Research
  7.2 Preclinical
  7.3 Phase-I
  7.4 Phase-I/II
  7.5 Phase-II
  7.6 Phase-II/III
  7.7 Phase-III
  7.8 Preregistration
  7.9 Registered
 
8. Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country & Indication
 
9. Antibody - Antibody Combinations – Pricing, Patent & Dosing Insight
 
  9.1 Opdivo + Yervoy
    9.1.1 Overview & Patent Insight
    9.1.2 Pricing & Dosage Insight
 
  9.2 Opdualag (nivolumab & relatlimab)
    9.2.1 Overview & Patent Insight
    9.2.2 Pricing & Dosage Insight
 
  9.3 Imjudo + Imfinzi
    9.3.1 Overview & Patent Insight
    9.3.2 Pricing & Dosage Insight
 
Detailed Combinations Are Mentioned in Report Sample
 
10. Antibody - Small Molecule Inhibitors Combinations – Pricing, Patent & Dosing Insight
 
  10.1 Gazyva + Imbruvica
    10.1.1 Overview & Patent Insight
    10.1.2 Pricing & Dosage Insight
 
  10.2 Imbruvica + Rituximab
    10.2.1 Overview & Patent Insight
    10.2.2 Pricing & Dosage Insight
 
  10.3 Bavencio + Inlyta
    10.3.1 Overview & Patent Insight
    10.3.2 Pricing & Dosage Insight
 
Detailed Combinations Are Mentioned in Report Sample
 
11. Antibody - Immunomodulatory Agents Combinations – Pricing, Patent & Dosing Insight
 
 11.1 Monjuvi + lenalidomide
    11.1.1 Overview & Patent Insight
    11.1.2 Pricing & Dosage Insight
 
  11.2 Avastin + Interferon-alfa
    11.2.1 Overview & Patent Insight
    11.2.2 Pricing & Dosage Insight
 
12. Antibody - Chemotherapy Combinations – Pricing, Patent & Dosing Insight
 
  12.1 Jemperli
    12.1.1 Overview & Patent Insight
    12.1.2 Pricing & Dosage Insight
 
  12.2 Cyramza
    12.2.1 Overview & Patent Insight
    12.2.2 Pricing & Dosage Insight
 
  12.3 Portrazza
    12.3.1 Overview & Patent Insight
    12.3.2 Pricing & Dosage Insight
 
  Detailed Combinations Are Mentioned in Report Sample
 
13. Antibody - Mixed Combinations
 
  13.1 Phesgo (Perjeta + Herceptin + hyaluronidase)
    13.1.1 Overview & Patent Insight
    13.1.2 Pricing & Dosage Insight
 
  13.2 Darzalex
    13.2.1 Overview & Patent Insight
    13.2.2 Pricing & Dosage Insight
 
  13.3 Empliciti
    13.3.1 Overview & Patent Insight
    13.3.2 Pricing & Dosage Insight
 
Detailed Combinations Are Mentioned in Report Sample
 
14. Competitive Landscape
  14.1 AbbVie
  14.2 Adagene
  14.3 Agenus
  14.4 Akeso Biopharma
  14.5 Amgen
  14.6 AstraZeneca
  14.7 BeiGene
  14.8 Biocad
  14.9 BioInvent International
  14.10 Bio-Thera Solutions
  14.11 Boehringer Ingelheim
  14.12 Bristol-Myers Squibb
  14.13 Concentra Biosciences
  14.14 Daiichi Sankyo Company
  14.15 Eli Lilly and Company
  14.16 Eucure Biopharma
  14.17 Genentech
  14.18 Genmab
  14.19 GSK
  14.20 ImmunoGen
  14.21 Innovent Biologics
  14.22 Janssen Research & Development
  14.23 Jiangsu Hengrui Medicine Co.
  14.24 LaNova Medicines Limited
  14.25 Lepu Biopharma
  14.26 MacroGenics
  14.27 Merck
  14.28 Merus
  14.29 NGM Biopharmaceuticals
  14.30 Novartis
  14.31 Pfizer
  14.32 Regeneron Pharmaceuticals
  14.33 Roche
  14.34 Seagen
  14.35 Shanghai Henlius Biotech
  14.36 Shanghai Junshi Biosciences
  14.37 Sinocelltech
  14.38 Symphogen
  14.39 UCB
  14.40 Xencor
 

List of Figures
 
 
Figure 1-1: Developmental Milestones for Antibody Combinations
 
Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination
 Therapy
Figure 2-2: Need of Antibody Combinations
Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents
Figure 2-4: Expected Antibody Combinations
 
Figure 3-1: Global – Cancer Antibody Combination Market Opportunity (US$ Billion),
 2023 - 2028
Figure 3-2: Antibody Combination Market - Prominent Regions
Figure 3-3: Aspects of Current Antibody Combinations Market
Figure 3-4: Future Characteristics of Antibody Combinations Market
 
Figure 4-1: COMBI-i Phase III Study – Initiation & Completion Years
Figure 4-2: CONTACT-01 Phase III Study – Initiation & Completion Years
Figure 4-3: NCT05800015 Phase II//III Study – Initiation & Completion Years
Figure 4-4: MagnetisMM-4 Phase II Study – Initiation & Completion Years
Figure 4-5: DREAMM 6 Phase I/II Study – Initiation & Completion Years
Figure 4-6: NCT04421352 Phase I Study – Initiation & Completion Year
Figure 4-7: NCT05867121 Phase I Study – Initiation & Completion Year
Figure 4-8: NCT06054477 Phase I/II Study – Initiation & Completion Year
Figure 4-9: NCT04868877 Phase I/II Study – Initiation & Completion Year
Figure 4-10: NCT05867121 Phase I Study – Initiation & Completion Year
Figure 4-11: NCT06038578 Phase II Study – Initiation & Completion Year
Figure 4-12: DESTINY-Breast01 Phase II Study – Initiation & Completion Year
Figure 4-13: BI-1607 & Trastuzumab Phase I/II Study – Initiation & Completion Year
Figure 4-14: Myechild01 Phase III Study – Initiation & Completion Year
Figure 4-15: GS-9911 & Zimberelimab Phase I Study – Initiation & Completion Year
Figure 4-16: EGIA-002 Phase II Study – Initiation & Completion Year
Figure 4-17: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
Figure 4-18: TUC1PI-01 Phase I/II Study – Initiation & Completion Year
Figure 4-19: LEAP-008 Phase III Study – Initiation & Completion Year
Figure 4-20: VOLGA Phase III Study – Initiation & Completion Year
Figure 4-21: MarkV-01 Phase I Study – Initiation & Completion Year
 
Figure 5-1: Global – Cancer Antibody Combinations Clinical Trials By Antibody
 Classification, 2023 till 2028
Figure 5-2: Global – Cancer Antibody Combinations Clinical Trials By Priority Status,
 2023 till 2028
Figure 5-3: Global – Cancer Antibody Combinations Clinical Trials By Company, 2023
 till 2028
Figure 5-4: Global – Cancer Antibody Combinations Clinical Trials By Country, 2023
 till 2028
Figure 5-5: Global – Cancer Antibody Combinations Clinical Trials By Indication, 2023
 till 2028
Figure 5-6: Global – Cancer Antibody Combinations Clinical Trials By Phase, 2023 till
 2028
 
Figure 6-1: Lung Cancer – Approved Antibody Combinations
Figure 6-2: Cemiplimab & Fianlimab Phase II/III Study – Initiation & Completion Year
Figure 6-3: Daratumumab, Nivolumab & KRAS vaccine Phase II Study – Initiation &
Completion Year
Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations
Figure 6-5: Melanoma – Approved Antibody Combinations
Figure 6-6: NCT05608291 Phase III Study – Initiation & Completion Year
Figure 6-7: OrienX010-II-11 Phase I Study – Initiation & Completion Year
Figure 6-8: MM1636 Phase I/II Study – Initiation & Completion Year
Figure 6-9: Breast Cancer - Approved Antibody Combinations
Figure 6-10: Trastuzumab & Pyrotinib Phase III Study – Initiation & Completion Year
Figure 6-11: Inetetamab, Toripalimab & Paclitaxel Phase IV Study – Initiation &
Completion Year
Figure 6-12: Breast Cancer – Key Player in Antibody Combination Commercial Market
Figure 6-13: Breast Cancer – Different Antibody Combination With Other
Therapeutic Agents
Figure 6-14: Hepatocellular Cancer– Approved Antibody Combinations
Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular
Carcinoma
Figure 6-16: Penpulimab & Anlotinib Phase III Study – Initiation & Completion Year
Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company
Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer
Figure 6-19: NCT06099951 Phase II Study – Initiation & Completion Year
Figure 6-20: KEYFORM-007 Phase III Study – Initiation & Completion Year
Figure 6-21: Renal Cell Carcinoma – Approved Antibody Combinations
Figure 6-22: SillaJen & Regeneron Pharmaceuticals – Novel Approach of Combining
Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma
Figure 6-23: BMC128 & Nivolumab Phase I Study – Initiation & Completion Year
Figure 6-24: Lymphoma – Approved Antibody Combinations
Figure 6-25: NCT04464798 Phase I Study – Initiation & Completion Year
Figure 6-26: Odronextamab, Lenalidomide & Rituximab Phase III Study – Initiation &
Completion Year
Figure 6-27: L-DEP & PD-1 Antibody Phase III Study – Initiation & Completion Year
Figure 6-28: Collaboration of MorphoSys & Incyte, IGM Bioscience & ADC
Therapeutic, 2022
Figure 6-29: Leukemia – Approved Antibody Combinations
Figure 6-30: NCT06043674 Phase II Study – Initiation & Completion Year
Figure 6-31: NP137, Venetoclax & Azacitidine Phase I/II Study – Initiation &
Completion Year
Figure 6-32: Novartis – Hypothesis for Phase 3 Clinical Study
Figure 6-33: Sabatolimab & Azacitidine Phase III Study – Initiation & Completion
Year
Figure 6-34: Multiple Myeloma – Approved Antibody Combinations
Figure 6-35: NCT05730036 Phase III Study – Initiation & Completion Year
Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple
Myeloma
Figure 6-37: NCT05363111 Phase I Study – Initiation & Completion Year
 
Figure 9-1: Opdivo & Yervoy – Minimum Market Exclusivity Year by Region
Figure 9-2: Opdivo & Yervoy – FDA Approval Years by Indications
Figure 9-3: Opdivo & Yervoy – EMA Approval Years by Indications
Figure 9-4: US – Opdivo Cost per Unit & Supply (US$), December’2023
Figure 9-5: US – Yervoy Cost per Unit & Supply (US$), December’2023
Figure 9-6: EU – Opdivo Cost of Supply (US$), November’2023
Figure 9-7: EU – Yervoy Cost of Supply (US$), November’2023
Figure 9-8: Opdualag – Approval Years by Region
Figure 9-9: Opdualag – Minimum Market Exclusivity Year by Region
Figure 9-10: US & EU – Opdualag Cost per Supply (US$), November’2023
Figure 9-11: Imfinzi & Imjudo – Patent Expiry Years by Region
Figure 9-12: US – Imfinzi Cost per Unit & Supply (US$), November’2023
Figure 9-13: US – Imjudo Cost per Unit & Supply (US$), November’2023
Figure 9-14: EU – Imfinzi Cost per Unit & Supply (US$), November’2023
Figure 9-15: EU – Imjudo Cost per Unit & Supply (US$), November’2023
Figure 9-16: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-17: US – Padcev Cost per Unit & Supply (US$), November’2023
Figure 9-18: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-19: EU – Padcev Cost per Unit & Supply (US$), November’2023
Figure 9-20: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-21: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 9-22: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 9-23: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 9-24: US – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 9-25: US – Avastin Cost per Unit & Supply (US$), November’2023
Figure 9-26: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
November’2023
Figure 9-27: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
November’2023
Figure 9-28: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &
160ml (US$), November’2023
Figure 9-29: EU – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 9-30: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
November’2023
Figure 9-31: US – Perjeta Cost per Unit & Supply (US$), November’2023
Figure 9-32: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 9-33: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 9-34: EU – Perjeta Cost per Supply (US$), November’2023
Figure 9-35: US – Polivy Cost per Supply (US$), November’2023
Figure 9-36: US – Rituxan Cost per Unit & Supply (US$), November’2023
Figure 9-37: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$),
November’2023
Figure 9-38: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$),
November’2023
Figure 9-39: EU – Polivy Cost per Supply (US$), November’2023
Figure 9-40: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),
November’2023
 
Figure 10-1: US – Imbruvica Cost per Unit & Supply of 70mg (US$), November’2023
Figure 10-2: US – Imbruvica Cost per Unit & Supply of 140mg (US$), November’2023
Figure 10-3: US – Gazyva Cost per Unit & Supply (US$), November’2023
Figure 10-4: US – Imbruvica Cost per Unit & Supply of 70mg (US$), November’2023
Figure 10-5: US – Imbruvica Cost per Unit & Supply of 140mg (US$), November’2023
Figure 10-6: US – Rituxan Cost per Unit & Supply (US$), November’2023
Figure 10-7: US – Rituximab Biosimilar Cost per Unit & Supply of 10ml (US$),
November’2023
Figure 10-8: US – Rituximab Biosimilar Cost per Unit & Supply of 50ml (US$),
November’2023
Figure 10-9: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),
November’2023
Figure 10-10: US – Bavencio Cost per Unit & Supply (US$), November’2023
Figure 10-11: US – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-12: EU – Bavencio Cost per Unit & Supply (US$), November’2023
Figure 10-13: EU – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-14: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-15: US – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-16: EU – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-17: EU – Inlyta Cost per Unit & Supply (US$), November’2023
Figure 10-18: US – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 10-19: US – Tarceva Cost per Supply (US$), December’2023
Figure 10-20: EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 10-21: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 10-22: US – Lenvima Cost per Unit & Supply (US$), November’2023
Figure 10-23: EU – Keytruda Cost per Unit & Supply (US$), December’2023
Figure 10-24: US – Opdivo Cost per Unit & Supply (US$), November’2023
Figure 10-25: US – Cabometyx Cost per Unit & Supply (US$), November’2023
Figure 10-26: EU – Opdivo Cost per Unit & Supply (US$), November’2023
Figure 10-27: EU – Cabometyx Cost per Unit & Supply (US$), November’2023
 
Figure 11-1: US – Monjuvi Cost of Supply (US$), December’2023
Figure 11-2: US – Revlimid Cost per Unit & Supply (US$), December’2023
Figure 11-3: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 11-4: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 11-5: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 11-6: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml &
160ml (US$), December’2023
Figure 11-7: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
 
Figure 12-1: US & EU – Jemperli Cost of Supply (US$), December’2023
Figure 12-2: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-3: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-4: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-5: US – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-6: EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-7: US – Taxotere Cost per Unit & Supply (US$), December’2023
Figure 12-8: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-9: US & EU – Cyramza Cost per Unit & Supply (US$), December’2023
Figure 12-10: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-11: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-12: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-13: US – Vectibix Cost per Unit & Supply (US$), December’2023
Figure 12-14: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-15: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-16: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-17: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-18: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-19: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-20: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December’2023
Figure 12-21: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-22: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-23: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-24: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-25: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-26: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-27: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-28: US – Vincristine Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-29: US – Toposar Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-30: US – Etoposide Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-31: US – Etoposide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-32: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$),
December’2023
Figure 12-33: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$),
December’2023
Figure 12-34: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$),
December’2023
Figure 12-35: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$),
December’2023
Figure 12-36: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 12-37: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$),
December’2023
Figure 12-38: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 12-39: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$),
December’2023
Figure 12-40: US – Vinblastine Cost per Unit & Supply (US$), December’2023
Figure 12-41: US – Dacarbazine Cost per Unit & Supply for 100mg Intravenous
Powder (US$), December’2023
Figure 12-42: US – Dacarbazine Cost per Unit & Supply for 200mg Intravenous
Powder (US$), December’2023
Figure 12-43: US – Erbitux Cost per Unit & Supply (US$), December’2023
Figure 12-44: US – Camptosar Cost per Unit & Supply (US$), December’2023
Figure 12-45: US – Irinotecan Cost per Unit & Supply (US$), December’2023
Figure 12-46: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-47: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-48: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-49: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-50: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-51: US – Leucovorin Cost of Supply of 100mg, 200mg, 350mg & 500mg
Injectable Powder (US$), December’2023
Figure 12-52: US – Leucovorin Cost per Unit & Supply of Injectable Solution (US$),
December’2023
Figure 12-53: US - Leucovorin Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 12-54: US - Leucovorin Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 12-55: US - Leucovorin Cost per Unit & Supply of 15mg Oral Tablet (US$),
December’2023
Figure 12-56: US - Leucovorin Cost per Unit & Supply of 25mg Oral Tablet (US$),
December’2023
Figure 12-57: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 12-58: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 12-59: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 12-60: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml
& 160ml (US$), December’2023
Figure 12-61: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
Figure 12-62: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-63: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-64: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-65: US – Tecentriq Cost per Unit & Supply (US$), November’2023
Figure 12-66: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-67: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-68: US – Hycamtin Cost of Supply of Oral Capsule (US$), December’2023
Figure 12-69: US – Topotecan Cost of Supply of Intravenous Solution (US$),
December’2023
Figure 12-70: US – Keytruda Cost per Unit & Supply (US$), November’2023
Figure 12-71: EU – Keytruda Cost of Supply (US$), November’2023
Figure 12-72: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 12-73: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 12-74: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 12-75: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-76: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-77: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-78: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml, & 500mg/ml (US$), December’2023
Figure 12-79: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-80: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-81: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-82: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-83: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-84: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-85: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-86: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-87: US – Abraxane Cost per Unit & Supply (US$), December’2023
Figure 12-88: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-89: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-90: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-91: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-92: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-93: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-94: US – Gemzar Cost of Supply (US$), December’2023
Figure 12-95: US – Infugem Cost per Unit & Supply (US$), December’2023
Figure 12-96: US – Gemcitabine Cost of Supply of Intravenous Powder for Injection
(US$), December’2023
Figure 12-97: US – Gemcitabine Cost per Unit & Supply of 38mg/ml Intravenous
Solution (US$), December’2023
Figure 12-98: US – Gemcitabine Cost per Unit & Supply of 100mg/ml Intravenous
Solution (US$), December’2023
Figure 12-99: US – Alimta Cost of Supply (US$), December’2023
Figure 12-100: US – Pemfexy Cost per Unit & Supply (US$), December’2023
Figure 12-101: US – Pemetrexed Cost per Unit & Supply of Intravenous Powder for
Injection (US$), December’2023
Figure 12-102: US – Pemetrexed Cost per Unit & Supply of Intravenous Solution
(US$), December’2023
Figure 12-103: US – Ellence Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-104: US – Epirubicin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-105: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 12-106: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 12-107: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 12-108: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 12-109: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 12-110: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 12-111: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 12-112: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-113: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Doses 1g/2ml, 2g/4ml & 500mg/ml (US$), December’2023
Figure 12-114: US – Cyclophosphamide Cost per Unit & Supply of Intravenous
Solutions of Dose 200mg/ml (US$), December’2023
Figure 12-115: US – Cyclophosphamide Cost per Unit & Supply of Oral Capsule (US$),
December’2023
Figure 12-116: US – Cyclophosphamide Cost per Unit & Supply of Oral Tablet (US$),
December’2023
Figure 12-117: US – Adriamycin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-118: US – Adriamycin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 12-119: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),
December’2023
Figure 12-120: US – Doxorubicin Cost per Unit & Supply of Intravenous Solution
(US$), December’2023
Figure 12-121: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-122: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 12-123: US – Libtayo Cost per Unit & Supply (US$), December’2023
Figure 12-124: US – Libtayo Cost per Unit & Supply (US$), December’2023
Figure 12-125: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 12-126: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 12-127: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 12-128: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 12-129: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 12-130: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
 
Figure 13-1: US – Phesgo Cost per Unit & Supply (US$), December’2023
Figure 13-2: EU – Phesgo Cost per Unit & Supply (US$), December’2023
Figure 13-3: US - Darzalex Cost per Unit & Supply (US$), November’2023
Figure 13-4: EU - Darzalex Cost per Unit & Supply (US$), December’2023
Figure 13-5: US – Kyprolis Cost per Unit & Supply (US$), November’2023
Figure 13-6: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable
Solution (US$), December’2023
Figure 13-7: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable
Solution (US$), December’2023
Figure 13-8: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023
Figure 13-9: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US$),
December’2023
Figure 13-10: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg, 1mg
& 6mg Oral Tablets (US$), December’2023
Figure 13-11: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets
(US$), December’2023
Figure 13-12: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets
(US$), December’2023
Figure 13-13: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets
(US$), December’2023
Figure 13-14: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets
 (US$), December’2023
Figure 13-15: US – TaperDex Cost per Unit & Supply (US$), December’2023
Figure 13-16: US – Velcade Cost per Supply (US$), November’2023
Figure 13-17: US – Bortezomib Cost of Supply (US$), December’2023
Figure 13-18: US – Thalomid Cost per Unit & Supply of 50mg Capsule (US$),
December’2023
Figure 13-19: US – Thalomid Cost per Unit & Supply of 100mg & 150mg Capsules
(US$), December’2023
Figure 13-20: US – Revlimid Cost per Unit & Supply (US$), December’2023
Figure 13-21: US – Pomalyst Cost per Unit & Supply (US$), December’2023
Figure 13-22: US – Evomela & Generic Melphalan Cost of Supply (US$),
December’2023
Figure 13-23: US – Prednisone Cost per Unit & Supply of 1mg/ml Oral Solution (US$),
December’2023
Figure 13-24: US – Prednisone Cost per Unit & Supply of 5mg/ml Oral Solution (US$),
December’2023
Figure 13-25: US – Prednisone Cost per Unit & Supply of 1mg Oral Tablet (US$),
December’2023
Figure 13-26: US – Prednisone Cost per Unit & Supply of 2.5mg Oral Tablet (US$),
December’2023
Figure 13-27: US – Prednisone Cost per Unit & Supply of 5mg Oral Tablet (US$),
December’2023
Figure 13-28: US – Prednisone Cost per Unit & Supply of 50mg Oral Tablet (US$),
December’2023
Figure 13-29: US – Prednisone Cost per Unit & Supply of 10mg Oral Tablet (US$),
December’2023
Figure 13-30: US – Prednisone Cost per Unit & Supply of 20mg Oral Tablet (US$),
December’2023
Figure 13-31: US - Empliciti Cost of Supply (US$), November’2023
Figure 13-32: US – Pomalyst Cost per Unit & Supply (US$), December’2023
Figure 13-33: US – Dexamethasone Cost per Unit & Supply of 4mg/ml Injectable
Solution (US$), December’2023
Figure 13-34: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Injectable
Solution (US$), December’2023
Figure 13-35: US – Dexamethasone Cost per Unit & Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023
Figure 13-36: US – Dexamethasone Cost per Unit & Supply of Oral Liquid (US$),
December’2023
Figure 13-37: US – Dexamethasone Cost per Unit & 100-Tablet Supply of 0.5mg,
1mg, & 6mg Oral Tablets (US$), December’2023
Figure 13-38: US – Dexamethasone Cost per Unit & Supply of 0.75mg Oral Tablets
(US$), December’2023
Figure 13-39: US – Dexamethasone Cost per Unit & Supply of 1.5mg Oral Tablets
(US$), December’2023
Figure 13-40: US – Dexamethasone Cost per Unit & Supply of 2mg Oral Tablets
(US$), December’2023
Figure 13-41: US – Dexamethasone Cost per Unit & Supply of 4mg Oral Tablets
(US$), December’2023
Figure 13-42: US – TaperDex Cost per Unit & Supply (US$), December’2023
Figure 13-43: US – Keytruda Cost per Unit & Supply (US$), December’2023
Figure 13-44: EU – Keytruda Cost of Supply (US$), December’2023
Figure 13-45: US – Herceptin Cost per Unit & Supply (US$), November’2023
Figure 13-46: US – Trastuzumab Biosimilar Cost per Unit & Supply (US$),
November’2023
Figure 13-47: US – Avastin Cost per Unit & Supply (US$), December’2023
Figure 13-48: US – Bevacizumab Biosimilar Cost per Unit & Supply for 4ml (US$),
December’2023
Figure 13-49: US – Bevacizumab Biosimilar Cost per Unit & Supply for 16ml (US$),
December’2023
Figure 13-50: US – Bevacizumab Biosimilar Alymsys Cost per Unit & Supply for 40ml
& 160ml (US$), December’2023
Figure 13-51: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),
December’2023
Figure 13-52: US – Paclitaxel Cost per Unit & Supply (US$), December’2023
Figure 13-53: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 13-54: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 13-55: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 13-56: US – Xeloda Cost per Unit & Supply (US$), November’2023
Figure 13-57: US – Capecitabine Cost per Unit & Supply of 150mg (US$),
November’2023
Figure 13-58: US – Capecitabine Cost per Unit & Supply of 500mg (US$),
November’2023
Figure 13-59: US – Adrucil Cost per Unit & Supply (US$), December’2023
Figure 13-60: US – Fluorouracil Cost per Unit & Supply (US$), December’2023
Figure 13-61: US – Cisplatin Cost per Unit & Supply for Intravenous Solution (US$),
December’2023
Figure 13-62: US – Paraplatin Cost per Unit & Supply (US$), December’2023
Figure 13-63: US – Carboplatin Cost per Unit & Supply (US$), December’2023
Figure 13-64: US – Eloxatin Cost per Unit & Supply (US$), December’2023
Figure 13-65: US – Oxaliplatin Cost per Unit & Supply of Intravenous Powder (US$),
December’2023
Figure 13-66: US – Oxaliplatin Cost per Unit & Supply of Intravenous Solution (US$),
December’2023
Figure 13-67: US – Sarclisa Cost per Unit & Supply (US$), December’2023
Figure 13-68: US – Kyprolis Cost per Unit & Supply (US$), December’2023
Figure 13-69: EU – Sarclisa Cost per Unit & Supply (US$), December’2023
Figure 13-70: US – Pomalyst Cost per Unit & Supply (US$), December’2023
 
 
List of Tables
 
Table 1-1: Global – Approved Cancer Antibody Combinations
 
Table 9-1: Opdivo & Yervoy Combination – Recommended Dosages
Table 9-2: Imjudo & Imfinzi - Recommended Dosage Schedule for Treatment of
 NSCLC
 
Table 10-1: Dose of Gazyva to be Administered During Six 28-Day Treatment Cycles
 for Patients with CLL
Table 10-2: Cabometyx & Nivolumab - Recommended Dosage of Combination
 
Table 11-1: Monjuvi - Dosing Schedule
 
Table 12-1: Jemperli - Recommended Dosage
Table 12-2: US – Approved Cyramza-Chemotherapy Combinations
Table 12-3: US – Approved Vectibix-Chemotherapy Combinations
Table 12-4: US – Approved Adcetris-Chemotherapy Combinations
Table 12-5: Adcetris - Recommended Dosage
Table 12-6: US – Approved Erbitux-Chemotherapy Combinations
Table 12-7: US – Approved Avastin-Chemotherapy Combinations
Table 12-8: US – Approved Keytruda-Chemotherapy Combinations
Table 12-9: Keytruda - Recommended Doses
Table 12-10: US – Approved Herceptin-Chemotherapy Combinations
 
Table 13-1: Phesgo: Recommended Dosage & Administration Schedule
Table 13-2: US – Approved Darzalex-Chemotherapy Combinations
Table 13-3: Darzalex - Dosing Schedule in Combination with Lenalidomide or
 Pomalidomide (4-Week Cycle) & Low-Dose Dexamethasone
Table 13-4: Darzalex - Dosing Schedule in Combination with Bortezomib, &
Prednisone ([VMP], 6-Week Cycle)
Table 13-5: Darzalex - Dosing Schedule in Combination with Bortezomib,
Thalidomide & Dexamethasone ([VTd]; 4-Week Cycle)
Table 13-6: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week
 Cycle)
Table 13-7: Darzalex - Dosing Schedule with Bortezomib & Dexamethasone (3-Week
Cycle)
Table 13-8: Empliciti - Recommended Dosing Schedule in Combination with
 Lenalidomide & Dexamethasone
Table 13-9: Empliciti - Recommended Dosing Schedule in Combination with
Pomalidomide & Dexamethasone
Table 13-10: US – Approved Keytruda-Chemotherapy Combinations
Table 13-11: Keytruda - Recommended Dosage
Table 13-12: US – Approved Sarclisa-Chemotherapy Combinations
Table 13-13: Sarclisa - Dosing Schedule in Combination with Pomalidomide &
Dexamethasone or in Combination with Carfilzomib & Dexamethasone